{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-051559","form_type":"8-K","ticker":"BRKR","cik":"0001109354","company_name":"BRUKER CORP","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.321290+00:00","generated_at":"2026-06-02T23:53:45.603881+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Bruker completes €870M cash acquisition of ELITechGroup; expects $0.08-0.10 EPS accretion","bullets":["Purchase price of €870 million in cash for ELITech, excluding clinical chemistry business.","ELITech FY2023 revenue ~€150M with >80% consumables; systems include InGenius and BeGenius MDx platforms.","Remainder 2024 expected ELITech revenue ~$100M within Bruker, non-GAAP EBIT margins >20%.","Non-GAAP EPS accretion of $0.08-$0.10 for FY 2024 after acquisition financing costs.","ELITech to become Bruker Molecular Diagnostics within Microbiology & Infection Diagnostics division."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-051559","json":"https://secwatch.observer/filing/0000950170-24-051559.json","markdown":"https://secwatch.observer/filing/0000950170-24-051559.md","text":"https://secwatch.observer/filing/0000950170-24-051559.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1109354/000095017024051559/0000950170-24-051559-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1109354/000095017024051559/brkr-20240502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T23:53:45.603881+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}